



**FOR IMMEDIATE RELEASE**

**Jounce Therapeutics Announces Presentation at the Leerink Partners  
Immuno-Oncology Roundtable**

**Cambridge, Mass., October 1, 2015** – Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015, at 1:30 p.m. ET. The conference is being held at the Le Parker Meridien Hotel in New York City.

**About Jounce Therapeutics**

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations leading to clinical trials with higher probability of success and rapid proof-of-concept. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce’s translational science platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit [www.jouncetx.com](http://www.jouncetx.com).

**Media Contact:**

Dan Budwick  
Pure Communications, Inc.  
(973) 271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

###